Search - tctmd.com

Displaying 1 - 20 of 280

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

Presentation EuroPCR 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presenter: Alexandre Abizaid

May 14, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

L.A. McKeown

May 31, 2023

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Daily News

DCB in Diabetes Show Promising Long-term Outcomes: BASKET-SMALL 2

L.A. McKeown

August 16, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Michael O'Riordan

March 01, 2021

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

DES Best for In-Stent Restenosis, but DCBs Also Viable

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

FDA Approves Bioresorbable Scaffold for BTK Lesions

Top Endovascular News of 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

SCAAR Registry Delves Into Left Main Revascularization Outcomes

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

DCB in Diabetes Show Promising Long-term Outcomes: BASKET-SMALL 2

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content